Virax Biolabs (NASDAQ:VRAX) Soars 183% After Fosun Deal

Virax Biolabs Group shares jumped more than 100% during Thursday’s U.S. session after the diagnostics company said its UK subsidiary reached an exclusive multi-country supply deal with Fosun Diagnostics for its ImmuneSelect research-use immune-profiling line. The Nasdaq stock was trading at $9.00 as of 11:52 a.m. EDT, up $5.82 on the day, with about 57.8 million shares changing hands.

9 July 2026

Company hubNASDAQ:VRAX

VRAX (VRAX) Stock News & Analysis

Follow the latest VRAX (VRAX) company news, earnings coverage and investor analysis from TechStock².

Save this hub to your TS2 Signalbook account.

Latest update: 9 July 2026
Articles in this hub: 3
Last 30 days: 0

What investors are watching

Earnings, guidance and financial performance
Valuation, trading activity and market sentiment
Strategy, catalysts and company-specific risks

Read latest coverage Prefer TechStock² in Google

Virax Biolabs Shares Jumping Again Ahead of Nasdaq Open

Virax Biolabs Group shares were higher again in early U.S. premarket trading Tuesday after a big move Monday. The thinly traded diagnostics micro-cap saw a spike in turnover as investors kept looking for a new catalyst.

19 May 2026

Biotechnology·Nasdaq·NASDAQ:VRAX·Stock Market

Why Virax Biolabs Stock Is Jumping Before the Bell Today

Virax Biolabs Group Limited shares were indicated sharply higher before the Nasdaq open on Monday, adding to a gain at Friday’s close, after the microcap diagnostics company appeared in a weekend sponsored television segment and a fresh ownership filing hit the tape.

18 May 2026

NASDAQ:VRAX·Stock Market